MBX Biosciences, Inc. (MBX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market
MBX Biosciences surged after canvuparatide's Phase 2 data showed strong efficacy and safety in hypoparathyroidism, addressing a significant unmet need. MBX's lead candidate outperformed placebo and could rival Yorvipath, the only approved therapy, with the added advantage of once-weekly dosing. MBX's pipeline includes early-stage GLP-1 assets targeting post-bariatric hypoglycemia and obesity, supported by a solid cash position into mid-2027.
MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy
MBX Biosciences offers a unique prodrug approach with three promising candidates targeting hypoparathyroidism, post-bariatric hypoglycemia, and obesity - two of its three drug candidates are GLP receptor agonists. Upcoming Phase 2 data for canvuparatide in hypoparathyroidism is a major near-term catalyst, with limited competition and potential for multi-billion dollar peak sales. Despite early-stage risks, MBX's strong management, solid cash position, and differentiated pipeline make it a more attractive value proposition than many GLP-1 peers.
MBX Biosciences raises $163.2 mln in US IPO
MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial public offering.
